Glioblastoma (GBM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Glioblastoma (GBM) is the most aggressive diffuse glioma of astrocytic lineage and is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy. 

GBM comprised of primary and secondary types, constituting distinct disease entities which evolve through different genetic pathways, affect patients at different ages, and likely differ in prognosis and response to therapy. 

Primary de novo GBM accounts for more than 80% of GBM (6), occurs in older patients (mean age = 64 years), and typically shows epidermal growth factor receptor (EGFR) over expression, PTN (MMC I) mutation, CDKN2A (p16) deletion, and less frequently MDM2 amplification. 

 

Epidemiology-

Glioblastoma has an incidence of 2 to 3.4 per 100,000 population in US and Europe.

 

The competitive landscape of Glioblastoma (GBM) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Glioblastoma (GBM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Glioblastoma (GBM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Glioblastoma (GBM) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset                           Company                                 Stage

1          Temozolomide  AbbVie  Phase 2

2          Dendritic vaccine pulsed with multiple peptides   Oncovir, Inc.            Phase 2

3          MK-3475           Merck Sharp & Dohme Corp.     Phase 2

4          2-OHOA           Laminar Pharmaceuticals           Phase 2

5          CTO     Tactical Therapeutics, Inc.         Phase 1

6          AMG 596          Amgen  Phase 1

7          MRZ     Celgene            Phase 2

8          TG02 capsules oral administration, BIW in every 28d      Lee's Pharmaceutical Limited  Phase 1

9          Bevacizumab    Hoffmann-La Roche      Phase 2

10        NTX-301           Xennials Therapeutics Australia Pty Ltd  Phase 2

Continue..
 

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more